Carl June

Carl June

Carl H. June is an American physician-scientist and immunologist noted for pioneering clinical applications of chimeric antigen receptor T cell therapy. He is a professor at the Perelman School of Medicine and a leader at the Abramson Cancer Center and the Center for Cellular Immunotherapies, with work bridging translational research, clinical trials, and biotechnology. June’s research has driven collaborations among academic centers, biotechnology companies, regulatory agencies, and patient advocacy groups.

Early life and education

June was born in Philadelphia and raised in Pennsylvania, attending public schools before matriculating at the University of Pennsylvania. He earned an undergraduate degree and then pursued graduate work at Yale University and medical training at the University of North Carolina School of Medicine. June completed residency and fellowship training in internal medicine and immunology at institutions including National Institutes of Health programs and clinical posts at major centers such as Children’s Hospital of Philadelphia.

Medical and research career

June joined the faculty of the Perelman School of Medicine at the University of Pennsylvania and established a laboratory at the Abramson Cancer Center. His work integrated techniques from cellular immunology, virology, and genetic engineering developed at laboratories like National Institutes of Health and incorporated findings from investigators at Fred Hutchinson Cancer Research Center, Dana-Farber Cancer Institute, and Memorial Sloan Kettering Cancer Center. He has collaborated with biotechnology firms including Novartis, Kite Pharma, and startups spun out of university technology transfer offices to translate laboratory discoveries into clinical-grade therapies. June’s publications appeared in journals such as Nature Medicine, The New England Journal of Medicine, and Science Translational Medicine, and he served on advisory panels for the Food and Drug Administration and the National Cancer Institute.

CAR T-cell therapy development

June led clinical trials demonstrating that genetically modified T cells expressing chimeric antigen receptors (CARs) could mediate durable remissions in refractory B-cell malignancies. His team engineered T cells to target CD19, produced ex vivo using viral vectors derived from research on lentivirus and retrovirus systems, and applied manufacturing practices consistent with Good Manufacturing Practice. Early compassionate-use cases and phase I/II trials were conducted at centers including Hospital of the University of Pennsylvania and coordinated with cooperative groups and regulatory bodies such as the FDA. These trials informed pivotal multicenter studies conducted by industry partners like Novartis and Juno Therapeutics, culminating in regulatory approvals of CAR T products for indications like refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. June’s group and collaborators addressed toxicities including cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome through interventions involving tocilizumab approvals and management protocols developed with intensive care teams and clinical pharmacology experts. Subsequent research expanded CAR designs to incorporate costimulatory domains inspired by studies at Scripps Research, antigen escape insights from Memorial Sloan Kettering Cancer Center, and combination strategies with checkpoint inhibitors investigated at MD Anderson Cancer Center and the Broad Institute.

Awards and honors

June’s contributions have been recognized with awards and honors from institutions including the American Association for Cancer Research, the National Academy of Medicine, and the American Society of Clinical Oncology. He has received distinguished prizes such as the National Medal of Technology and Innovation-level recognitions in biomedical translation contexts, society lectureships from American Society of Hematology, and international awards presented by organizations like the European Society for Medical Oncology. June holds elected membership in organizations including the National Academy of Sciences and advisory roles with foundations such as the Bill & Melinda Gates Foundation and the Pew Charitable Trusts.

Personal life and legacy

June is married with family ties in the Philadelphia region and maintains active roles in mentoring clinician-scientists at institutions such as Perelman School of Medicine and Children’s Hospital of Philadelphia. His legacy includes training generations of investigators who have founded biotechnology companies, led academic programs at centers like Stanford University and University of California, San Francisco, and advanced cellular immunotherapy platforms applied in oncology and autoimmune disease research. The clinical translation of CAR T-cell therapy under June’s leadership reshaped treatment paradigms at hospitals including Massachusetts General Hospital and influenced regulatory science at the Food and Drug Administration, leaving a sustained impact on oncology practice, biotechnology innovation, and patient advocacy networks.

Category:American immunologists Category:Physician-scientists